Mumps infectious disease
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- A contagious viral infection caused by the mumps virus. Symptoms include swollen and tender parotid glands, fever, muscle aches and fatigue. Due to vaccination programs, mumps has become a rare disease.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Mumps infectious disease
- Therapeutic area
- Infectious Disease
- mumps infectious disease
- Mumps
- Mumps virus caused disease or disorder
- Mumps virus disease or disorder
- Mumps virus infectious disease
- epidemic parotitis
- mumps
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Mild
- MONDO ID
- MONDO:0000989
- Parent condition
- MONDO:0005896
Related records
Broader conditions (9)
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
- Mononegavirales infectious disease
- Paramyxoviridae infectious disease
- Primary viral infectious disease
- Viral infectious disease
Narrower conditions (1)
- Congenital mumps
Trials (81)
- 300 Antibody Diagnostic Test Kit
- A Phase 1 Trial of Intranasal Mumps Virus Vaccines in Healthy Adults
- A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children
- A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
- A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)
- A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)
- A Study of ProQuad™ in Healthy Children in Korea (V221-023)
- A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
- A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
- Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.
- Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine
- Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)
- Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
- Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
- Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
- Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age
- Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines
- Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)
- Immune Responses to Two Dose Varivax +/- MMR-II
Approved drugs (1)
- Mumps virus, live attenuated
Drugs in development (1)
- Mumps virus vaccine live Phase 3
Other linked drugs (3)
- Botulinum toxin type A
- Measles virus, live attenuated
- Rubella virus, live attenuated